First-in-Human Study of INT-1B3 in Patients With Advanced Solid Tumors

Summary

This is a 2 part, multi-center, open-label, First-in-Human clinical study to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of INT-1B3 in the treatment of patients with advanced solid tumors.

Timeline

Start

2020-12-18

Primary completion

2023-03-24

Completion

2023-03-24

Outcome

Outcome not reported

Stopped (Business): “insufficient funding”

Drugs

Indications